About Eternygen
Eternygen GmbH, based in Berlin, was founded in 2012 and researches and develops innovative drugs in collaboration with a network of internationally renowned researchers and research companies. Eternygen's core competence lies in the research and development of drugs for nutrition-related metabolic diseases, which have increased massively worldwide in recent decades. The focus is on the sodium-coupled citrate transporter NaCT, a key protein in fat metabolism, which is a promising target for the treatment of fatty liver, diabetes as well as obesity.
The aim is to develop a drug that addresses these widespread diseases effectively and particularly safely through targeted correction of the causative metabolic defect.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Pharma
